Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 66,700 shares, a growth of 46.6% from the February 13th total of 45,500 shares. Based on an average daily volume of 6,080,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.6% of the shares of the stock are short sold.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.
Get Our Latest Analysis on PHIO
Phio Pharmaceuticals Trading Down 3.0 %
Institutional Trading of Phio Pharmaceuticals
A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC bought a new stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned 0.59% of Phio Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 57.31% of the stock is owned by institutional investors.
Phio Pharmaceuticals Company Profile
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Featured Stories
- Five stocks we like better than Phio Pharmaceuticals
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Insider Trading – What You Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.